Lumber Liquidators Holdings, Inc. (NYSE:LL) rose 2% in last session, following Raymond James raised the lumber retailer on the faith that the headwinds associated to concerns in excess of Chinese-made laminated flooring will dissipate and that sales and earnings trends will persist to improve. Analyst Budd Bugatch lifted that it his rating to outperform from market perform and set a $40 stock price target, which is 20 percent above Thursday’s closing price of $33.20. Bugatch stated a Raymond James commissioned tests on two Chinese-made laminated wood floor products showed that formaldehyde emissions were significantly sealed in. Bugatch articulated in a note to clients that though the near term will stay challenging for the firm by both the loss of reputation and by the a variety of consumer and shareholder derivative lawsuits it will have to defend, they think the trend of sales, earnings and share value will track higher over the longer term. Lumber Liquidators Holdings, Inc. (NYSE:LL) to close at $34.09 by knocking up 2.68% with session volume was recorded 6.63 Million.
Clovis Oncology, Inc. (NASDAQ:CLVS) stated that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for the firm’s inspectional agent rucaparib as monotherapy treatment of innovative ovarian cancer in patients who have received at least two lines of prior platinum containing therapy, with BRCA-mutated tumors, inclusive of both germline BRCA and somatic BRCA mutations. Rucaparib is an oral, potent inhibitor of PARP1 and PARP2 being developed for the treatment of platinum-sensitive ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, commonly referred to as “BRCA-like” or “BRCAness.” The Breakthrough Therapy designation was granted based on interim efficacy and safety results from two ongoing Phase 2 studies of rucaparib in ovarian cancer, including a Phase 2 study in women with gBRCA mutations, and the ARIEL2 treatment study. The Breakthrough Therapy designation is intended to expedite development and review of drugs to treat serious or life-threatening medical conditions when preliminary clinical evidence demonstrates that the drug may have substantial improvement on at least one clinically significant endpoint over available therapies. Breakthrough Therapy designation includes all the features of the Fast Track designation, as well as more intensive guidance from the FDA on a drug’s clinical development program. Clovis Oncology, Inc. (NASDAQ:CLVS) declines -1.27% to closed at $68.64 as compare to its fifty-two week range of 35.33 – 83.46. The total market capitalization remained 2.33 Billion. The firm is ahead its 52 week low of 94.28% and going down from its 52 week high price of -17.76%.
Williams Partners L.P. (NYSE:WPZ) recently accepted to acquire an extra 21% equity interest in Utica East Ohio Midstream LLC or UEO, from a subsidiary of EV Energy Partners, L.P. (EVEP) for nearly $575 million in cash. Williams Partners anticipates the fixed-fee business will be accretive to the company beginning in 2015. The deal is expected to close by the middle of July 2015. “Acquiring these cash-generating assets supports our strategy to grow our natural gas midstream position in key basins. This fixed-fee business will be accretive to Williams Partners beginning in 2015 and the partnership has attractive growth opportunities as the Utica continues to develop,” said Alan Armstrong, CEO of the general partner of Williams Partners. UEO is a joint project to develop infrastructure for the gathering, processing and fractionation of natural gas and natural gas liquids in the Utica Shale play in eastern Ohio. Williams Partners already owns 49 percent equity interest in UEO through its subsidiary Utica Gas Services. Following the completion of the current deal, Williams Partners will own a 70 percent equity interest in UEO. However, Williams Partners noted that the other member of UEO has the right to acquire a portion of EV Energy Partners’ interests in UEO for the same price. If the other member exercises this right, Williams Partners would end up acquiring only about 13 percent interest, while the other member would acquire about 8 percent interest. Williams Partners L.P. (NYSE:WPZ) decreased -2.13% to close the session at $47.72 having average volume of 1338.50.
TELUS Corporation (NYSE:TU) reported the firm anticipates to invest $4.2 billion in current infrastructure and facilities across Alberta through 2018, including $1 billion in the this year alone. The firm stated, combined with operational expenses, this will bring the total TELUS investment in Alberta over the next four years to more than $11 billion. The company noted that the announced capital investment is consistent with its overall capital expenditure guidance for 2015, issued on February 12, 2015. While, TELUS Corporation (NYSE:TU) closed at $33.99 with eases up of 0.77% in last trading session. The firm has annual sales growth for the past five year of 4.50%. While past twelve months price to sales ratio recorded as 2.16 and price to cash ratio remained 431.98.